Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial.
作者信息
Thompson Peter L, Nidorf S Mark
机构信息
Heart Research Institute, Harry Perkins Institute of Medical Research, University of Western Australia and Genesis HeartCare Western Australia, Perth, Australia.
出版信息
J Thorac Dis. 2018 Feb;10(2):695-698. doi: 10.21037/jtd.2018.01.119.
Abstract
摘要
相似文献
1
Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trial.卡那单抗用于动脉粥样硬化疾病的抗炎治疗：来自CANTOS试验的经验教训。
J Thorac Dis. 2018 Feb;10(2):695-698. doi: 10.21037/jtd.2018.01.119.
2
Canakinumab and cardiovascular outcomes: results of the CANTOS trial.卡那单抗与心血管结局：CANTOS试验结果
J Community Hosp Intern Med Perspect. 2018 Feb 6;8(1):21-22. doi: 10.1080/20009666.2018.1428023. eCollection 2018.
3
Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).白介素-6 信号通路的调节与动脉粥样硬化事件和全因死亡率的发生率：来自卡那单抗抗炎血栓形成结局研究（CANTOS）的分析。
Eur Heart J. 2018 Oct 7;39(38):3499-3507. doi: 10.1093/eurheartj/ehy310.
4
Role of Anti-inflammatory Interventions in Coronary Artery Disease: Understanding the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).抗炎干预在冠状动脉疾病中的作用：了解卡那单抗抗炎血栓形成结果研究（CANTOS）。
Eur Cardiol. 2018 Aug;13(1):38-41. doi: 10.15420/ecr.2018.11.1.
5
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.卡那单抗治疗后 C 反应蛋白降低与心血管事件减少的关系：来自 CANTOS 随机对照试验的二次分析。
Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3. Epub 2017 Nov 13.
6
Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).白细胞介素-1β 抑制与复发性心血管事件的预防：卡那奴单抗抗炎血栓结局研究（CANTOS）的原理和设计。
Am Heart J. 2011 Oct;162(4):597-605. doi: 10.1016/j.ahj.2011.06.012. Epub 2011 Sep 14.
7
Canakinumab for secondary prevention of atherosclerotic disease.卡那奴单抗用于动脉粥样硬化疾病的二级预防。
Expert Opin Biol Ther. 2018 Feb;18(2):215-220. doi: 10.1080/14712598.2018.1420776. Epub 2017 Dec 27.
8
Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).卡那单抗抑制白细胞介素-1β与降低肺癌——卡那单抗抗炎血栓形成结局研究试验（CANTOS）的亚组分析
J Thorac Dis. 2018 Sep;10(Suppl 26):S3084-S3087. doi: 10.21037/jtd.2018.07.50.
9
Antiinflammatory Therapy in Clinical Care: The CANTOS Trial and Beyond.临床护理中的抗炎治疗：CANTOS试验及其他
Front Cardiovasc Med. 2018 Jun 5;5:62. doi: 10.3389/fcvm.2018.00062. eCollection 2018.
10
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.用卡那奴单抗进行抗炎治疗以预防和管理糖尿病。
J Am Coll Cardiol. 2018 May 29;71(21):2392-2401. doi: 10.1016/j.jacc.2018.03.002. Epub 2018 Mar 12.
引用本文的文献
1
Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.神经炎症：神经系统疾病中的机制、双重作用及治疗策略
Curr Issues Mol Biol. 2025 Jun 4;47(6):417. doi: 10.3390/cimb47060417.
2
Mechanotransduction for therapeutic approaches: Cellular aging and rejuvenation.用于治疗方法的机械转导：细胞衰老与年轻化
APL Bioeng. 2025 Jun 6;9(2):021502. doi: 10.1063/5.0263236. eCollection 2025 Jun.
3
Inflammasomes: novel therapeutic targets for metabolic syndrome?炎性小体：代谢综合征的新型治疗靶点？
Front Endocrinol (Lausanne). 2025 May 13;16:1569579. doi: 10.3389/fendo.2025.1569579. eCollection 2025.
4
Foamy macrophages in atherosclerosis: unraveling the balance between pro- and anti-inflammatory roles in disease progression.动脉粥样硬化中的泡沫巨噬细胞：揭示疾病进展中促炎和抗炎作用之间的平衡
Front Cardiovasc Med. 2025 May 2;12:1589629. doi: 10.3389/fcvm.2025.1589629. eCollection 2025.
5
Predictive value of cumulative SII for MACE in STEMI patients after PCI.经皮冠状动脉介入治疗后ST段抬高型心肌梗死患者中累积全身炎症反应指数对主要不良心血管事件的预测价值
Medicine (Baltimore). 2025 Mar 28;104(13):e41983. doi: 10.1097/MD.0000000000041983.
6
Systemic inflammation prevalence in patients with atherosclerotic cardiovascular disease and chronic kidney disease: a population-based study using a nationwide primary care database in Spain.动脉粥样硬化性心血管疾病和慢性肾脏病患者的全身炎症患病率：一项基于西班牙全国初级保健数据库的人群研究。
Front Cardiovasc Med. 2025 Mar 4;12:1538466. doi: 10.3389/fcvm.2025.1538466. eCollection 2025.
7
Association of systemic inflammatory response index and stroke: a cross-sectional study of NHANES, 2005-2018.全身炎症反应指数与中风的关联：2005 - 2018年美国国家健康与营养检查调查的横断面研究
Front Neurol. 2025 Jan 31;16:1538352. doi: 10.3389/fneur.2025.1538352. eCollection 2025.
8
Inflammatory Pathways in Coronary Artery Disease: Which Ones to Target for Secondary Prevention?冠状动脉疾病中的炎症通路：二级预防应针对哪些通路？
Cells. 2025 Jan 21;14(3):153. doi: 10.3390/cells14030153.
9
Human and gut microbiota synergy in a metabolically active superorganism: a cardiovascular perspective.代谢活跃的超级生物体中人与肠道微生物群的协同作用：心血管视角
Front Cardiovasc Med. 2024 Oct 11;11:1411306. doi: 10.3389/fcvm.2024.1411306. eCollection 2024.
10
Emerging Trends and Innovations in the Treatment and Diagnosis of Atherosclerosis and Cardiovascular Disease: A Comprehensive Review towards Healthier Aging.动脉粥样硬化与心血管疾病治疗和诊断的新趋势与创新：迈向健康老龄化的全面综述
Pharmaceutics. 2024 Aug 3;16(8):1037. doi: 10.3390/pharmaceutics16081037.
本文引用的文献
1
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.卡那单抗治疗后 C 反应蛋白降低与心血管事件减少的关系：来自 CANTOS 随机对照试验的二次分析。
Lancet. 2018 Jan 27;391(10118):319-328. doi: 10.1016/S0140-6736(17)32814-3. Epub 2017 Nov 13.
2
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study.秋水仙碱治疗急性冠状动脉综合征患者及稳定斑块：一项 CT 冠状动脉造影研究。
JACC Cardiovasc Imaging. 2018 Feb;11(2 Pt 2):305-316. doi: 10.1016/j.jcmg.2017.08.013. Epub 2017 Oct 18.
3
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.卡那单抗抑制白细胞介素-1β对动脉粥样硬化患者肺癌发病的影响：一项随机、双盲、安慰剂对照试验的探索性结果。
Lancet. 2017 Oct 21;390(10105):1833-1842. doi: 10.1016/S0140-6736(17)32247-X. Epub 2017 Aug 27.
4
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.卡那奴单抗治疗动脉粥样硬化疾病的抗炎疗法。
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
5
Targeting Inflammation in Coronary Artery Disease.针对冠状动脉疾病中的炎症
N Engl J Med. 2017 Sep 21;377(12):1197-1198. doi: 10.1056/NEJMe1709904. Epub 2017 Aug 27.
6
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.合成和生物 DMARDs 的安全性：系统文献综述为 2016 年更新的 EULAR 类风湿关节炎管理建议提供信息。
Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15.
7
Colchicine for prevention of cardiovascular events.秋水仙碱用于预防心血管事件。
Cochrane Database Syst Rev. 2016 Jan 27;2016(1):CD011047. doi: 10.1002/14651858.CD011047.pub2.
8
Novel anti-inflammatory therapies for the treatment of atherosclerosis.新型抗炎疗法治疗动脉粥样硬化。
Atherosclerosis. 2015 Jun;240(2):497-509. doi: 10.1016/j.atherosclerosis.2015.04.783. Epub 2015 Apr 18.
9
The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study.白细胞介素-1受体拮抗剂治疗对非ST段抬高型急性冠状动脉综合征炎症标志物的影响：MRC-ILA心脏研究
Eur Heart J. 2015 Feb 7;36(6):377-84. doi: 10.1093/eurheartj/ehu272. Epub 2014 Jul 30.
10
Methotrexate for treating rheumatoid arthritis.甲氨蝶呤用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD000957. doi: 10.1002/14651858.CD000957.pub2.
Zotero 插件